

September 12, 2023

**BSE Limited** 

1st Floor, New Trading Wing, Rotunda Building, P. J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635 **National Stock Exchange of India Limited** 

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA

Dear Sir / Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations')

In accordance with the provisions of Regulation 30 of the SEBI Listing Regulations, we wish to inform you that pursuant to an intimation received from Legal Affairs Bureau, Tokyo (the 'Authority') on September 12, 2023, voluntary liquidation of Piramal Pharma Japan GK, a step-down wholly - owned subsidiary of the Company has been approved by the Authority.

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given under Annexure A.

Request you to please take the above on record and oblige.

Thanking you,

Yours truly,

For Piramal Pharma Limited

Tanya Sanish Company Secretary



## Annexure A

| Sr.<br>No | Details of the events that need to be provided  | Information of such event(s)           |
|-----------|---|--|
| 1.        | The amount and percentage of the turnover   | Turnover – Nil                         |
|           | or revenue or income and net worth  | Net worth – net worth contribution by  |
|           | contributed by such subsidiary of the listed  | Piramal Pharma Japan GK into the       |
|           | entity during the last financial year   | Company is JPY 45,59,118 equivalent to |
|           |   | INR 0.48 Crores (0.01%)                |
| 2.        | Date on which the agreement for sale has  | Not Applicable                         |
|           | been entered into   |  |
| 3.        | The expected date of completion of sale/disposal  | Not Applicable                         |
| 4.        | Consideration received from such sale/disposal  | Not Applicable                         |
| 5.        | Brief details of buyers and whether any of<br>the buyers belong to the promoter/promoter<br>group/group companies. If yes, details<br>thereof                                     | Not Applicable                         |
| 6.        | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"  | Not Applicable                         |
| 7.        | Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations | Not Applicable                         |
| 8.        | Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale           | Not Applicable                         |